PremiumThe FlyLumos Pharma downgraded to Neutral from Buy at H.C. Wainwright Lumos Pharma downgraded to Hold from Buy at JonesResearch Lumos Pharma reports Q3 net loss $7.5M PremiumCompany AnnouncementsLumos Pharma Announces Governance Decisions and Trial Updates Lumos Pharma announces results from FDA meeting on LUM-201 Lumos Pharma reports Q1 EPS ($1.29), consensus ($1.18) PremiumThe FlyLumos Pharma promotes Pisit Pitukcheewanont, MD to CMO, effective January 1 Lumos Pharma announces OraGrowtH210, OraGrowtH212 meet all endpoints Lumos Pharma reports Q3 EPS ($1.04), consensus ($1.15) 
